Relationship expert teams up with Pfizer to address intimacy and relationship issues for people living with chronic diseases
- Details
- Category: Pfizer
Nationally-recognized relationship expert and author, Logan Levkoff, Ph.D., has partnered with Pfizer Inc. (NYSE:PFE) to fill a void in information available to people living with chronic diseases: relationship advice. Levkoff will address the topics of relationships and intimacy for those living with a chronic condition, like rheumatoid arthritis (RA), on the newly re-launched Arthritis.com site.
Cladribine tablets significantly reduced brain atrophy in patients with multiple sclerosis
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced the publication of the results of a post hoc analysis of the Phase III CLARITY study in Multiple Sclerosis Journal. The analysis showed that Cladribine Tablets reduced the annualised rate of brain volume loss - also known as brain atrophy - compared with placebo in patients with relapsing remitting multiple sclerosis (RRMS).
Regorafenib granted priority review in the U.S. for second-line treatment of liver cancer
- Details
- Category: Bayer
Bayer announced that the U.S. Food and Drug Administration (FDA) has granted priority review designation to the supplemental New Drug Application (sNDA) for regorafenib for the second-line treatment of patients with unresectable hepatocellular carcinoma (uHCC) in the U.S.
Amgen announces Repatha® (evolocumab) significantly reduced the risk of cardiovascular events in FOURIER outcomes study
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) has announced that the FOURIER trial evaluating whether Repatha® (evolocumab) reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) met its primary composite endpoint (cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or coronary revascularization) and the key secondary composite endpoint (cardiovascular death, non-fatal MI or non-fatal stroke).
Roche reports good results in 2016
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the Group sales rose 4% to CHF 50.6 billion. Despite high investments in the launch of new products and product development, core EPS grew faster than sales (+5%). Core EPS growth reflects the good underlying business performance and an impact from changes to the Group's Swiss pension plans.
Pfizer reports fourth-quarter and full-year 2016 results
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2016 and provided 2017 financial guidance. Pfizer manages its commercial operations through two distinct businesses: Pfizer Innovative Health (IH) (formerly the Innovative Products business) and Pfizer Essential Health (EH) (formerly the Established Products business).
Novo Nordisk enters collaboration with University of Oxford on type 2 diabetes and invests GBP 115m in new research centre
- Details
- Category: Novo Nordisk
University of Oxford and Novo Nordisk today announced a landmark research collaboration focused on type 2 diabetes. The partnership will enable scientists from Novo Nordisk and University of Oxford to collaborate to discover innovative approaches for treating type 2 diabetes. As part of the collaboration, Novo Nordisk is also investing in a new research centre on the premises of the University of Oxford.
More Pharma News ...
- CUBE Challenge 2017: One Year. One Competition. One Million.
- Bristol-Myers Squibb reports fourth quarter and full year 2016 financial results
- Symbicort granted paediatric exclusivity in the US
- Abbott reports fourth-quarter 2016 results
- Novartis delivered solid 2016 performance
- AstraZeneca expands 1st-line lung cancer Immuno-Oncology programme opportunities
- Merck announces research collaboration with Domain Therapeutics in immuno-oncology